RARE CANCERS NEEDS A BREAKTHROUGH — IN FUNDING
About half of everyone with cancer has a rare cancer – yet research is underfunded.Donate now
Rare cancer research breakthroughs are not rare at all at MSK — here are four game-changers.
Your Vision Saves Theirs
Retinoblastoma is a rare cancer of the eye that affects mostly young children. Historically we have seen survival rates around 50% — and eye loss rates of 90%. But thanks to an innovative ophthalmic artery chemosurgery method developed by MSK, the outlook today is worlds better — a 99% survival rate and only a 5% eye loss.
FDA Approval Means New Hope for Pancreatic Patients
MSK oncologist Eileen O’Reilly led a clinical trial that discovered patients with BRCA1 and BRCA2 genes are responsive to the drug olaparib. As of December 21, 2019, the drug is FDA-approved and providing new hope to Stage IV pancreatic patients.
A Smarter Way to Track Brain Tumors
Brain tumors are notoriously tough to track. But brain tumors shed bits of their DNA — and that DNA finds its way into spinal fluid. An MSK team discovered how to analyze that fluid and track brain tumors with unheard-of precision — so doctors can see which treatment works best.
A Less Toxic Treatment for Kids
Young bodies are more vulnerable to chemotherapy and radiation so MSK doctors are always looking for alternative ways to slow a tumor’s progress. An MSK-led clinical trial led to the development of larotrectinib, the world’s first FDA approved drug designed to target a specific mutation. Now more kids have a new treatment alternative to chemotherapy.
Your rare cancer dollars go further hereDonate Now